Statins reduce cardiovascular events in primary and secondary prevention trials without causing an increase in carcinoma

Journal of the American Geriatrics Society

Volumn 57, Issue 10, 2009, Pages 1942-1943

  Aronow, Wilbert S ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CANCER INCIDENCE; CARCINOMA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; HUMAN; LETTER; MEDICAL LITERATURE; MEDICAL RESEARCH; PRIMARY PREVENTION; SECONDARY PREVENTION;

AGED; CARCINOMA; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRIMARY PREVENTION; SECONDARY PREVENTION;

EID: 70350426230     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2009.02456.x     Document Type: Letter

References (9)

1. Mascitelli L, Pezzetta F. Senator John McCain's health status and the arrogance of preventive medicine. J Am Geriatr Soc 2009 57 : 739 740.
2. Ford I, Murray H, Packard CJ et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007 357 : 1477 1486.
3. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998 279 : 1615 1622.
4. Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003 361 : 1149 1158. (Pubitemid 36398384)
5. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 2004 364 : 685 696.
6. Ridker PM, Danielson E, Fonseca FAH et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008 359 : 2195 2207.
7. Aronow WS. Managing hyperlipidaemia in the elderly. Special considerations for a population at high risk. Drugs Aging 2006 23 : 181 189.
8. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005 366 : 1267 1278.
9. Dale KM, Coleman CI, Henyan NN et al. Statins and cancer risk. A meta-analysis. JAMA 2006 295 : 74 80.